Poor
Not Aligned
Patient Risk:
Low
Summary
All extracted claims are not present in the provided FDA labeling excerpts, making them unsupported by the official prescribing information as supplied.
Category Scores
Accurate Statements
Unsupported Statements
Lipitor was first approved by the FDA in 1996.
Not present in labeling excerpts provided; approval date not verifiable from the supplied label.
The patent for Lipitor expired on November 30, 2011.
Patent/exclusivity details are not described in FDA labeling; not verifiable from the provided label.
Lipitor is manufactured by Pfizer.
Manufacturer/sponsor information not provided in the supplied label excerpts.
The introduction of generic Lipitor led to a 75% reduction in the price of the medication.
Pricing dynamics and generic market effects are not described in the provided labeling.
Generic Lipitor was non-inferior to the branded Lipitor in terms of lipid-lowering efficacy.
Comparative efficacy between brand and generic products is not a labeled claim in the provided excerpts.
Patients who switched to generic Lipitor had similar adherence rates to those who remained on branded Lipitor.
Adherence data comparing generics vs brand are not included in the provided labeling.
The average cost of generic Lipitor was $3.50 per day.
Pricing information is not contained in FDA labeling.
The average cost of branded Lipitor was $8.50 per day.
Pricing information is not contained in FDA labeling.
The patent expiration of Lipitor led to increased competition.
Patent/market competition effects are not described in the provided labeling sections.
The patent expiration of Lipitor led to reduced prices.
Labeling does not address patent expirations or drug pricing changes due to competition.
The introduction of generic Lipitor has led to significant cost savings.
Cost-savings claims relate to pricing/payer analyses and are not part of standard labeling.
Lipitor is a cholesterol-lowering medication.
Indication/classification details are not available in the provided label excerpts; require full labeling to confirm.
Contradictions
Important Omissions
Label excerpts are incomplete; critical sections such as Indication and Usage, Dosage and Administration, Contraindications, Warnings/Precautions, Drug Interactions, Use in Specific Populations, and Adverse Reactions are not provided for evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No safety-related claims were evaluated from the provided labeling excerpts; the content focuses on historical/purchasing/market aspects not safety.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
All extracted claims are not supported by the provided FDA labeling excerpts.
Suggested Improvement
Provide the full FDA-approved prescribing information or ensure that extracted claims exactly match labeled content to enable proper verification.